4.7 Article

Design, dynamic docking, synthesis, and in vitro validation of a novel DNA gyrase B inhibitor

出版社

TAYLOR & FRANCIS INC
DOI: 10.1080/07391102.2022.2107073

关键词

Staphylococcus aureus; Novobiocin; Rhodanine; De novo-based drug design; gyrase inhibitor; antibacterial resistance

向作者/读者索取更多资源

Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-intermediate-resistant Staphylococcus aureus (VRSA) are high priority pathogens according to the WHO. This study focuses on the urgent need for new classes of anti-MRSA drugs and targets the GyrB subunit of bacterial DNA Gyrase. Through structure-based virtual screening and de novo ligand design, the most promising ligand qsl-304 was identified. In vitro experiments showed qsl-304's activity against the novobiocin resistant clinical isolate, Staphylococcus aureus sa-P2003, and its bacteriostatic nature with reduced resistance recurrence.
Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-intermediate-resistant Staphylococcus aureus (VRSA) are among the WHO's high priority pathogens. Among these two, MRSA is the most globally documented pathogen that necessitates the pressing demand for new classes of anti-MRSA drugs. Bacterial gyrase targeted therapeutics are unique strategies to overcome cross-resistance as they are present only in bacteria and absent in higher eukaryotes. The GyrB subunit is essential for the catalytic functions of the bacterial enzyme DNA Gyrase, thereby constituting a promising druggable target. The current study performed a structure-based virtual screening to designing GyrB target-specific candidate molecules. The de novo ligand design of novel hit molecules was performed using a rhodanine scaffold. Through a systematic in silico screening process, the hit molecules were screened for their synthetic accessibility, drug-likeness and pharmacokinetics properties in addition to its target specific interactions. Of the 374 hit molecules obtained through de novo ligand design, qsl-304 emerged as the most promising ligand. The molecular dynamic simulation studies confirmed the stable interaction between the key residues and qsl-304. qsl-304 was synthesized through a one-step chemical synthesis procedure, and the in vitro activity was proven, with an IC50 of 31.23 mu g/mL against the novobiocin resistant clinical isolate, Staphylococcus aureus sa-P2003. Further studies on time-kill kinetics showed the bacteriostatic nature with the diminished recurrence of resistance. The on-target gyrB inhibition further proved the efficacy of qsl-304. Communicated by Ramaswamy H. Sarma

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据